Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald Hoffman

Showing results (201-210 of 204) with videos related to

Pageof 21
Sort By:
You have reached the last page of results.This site can display upto 204 results.
Blood|February 17, 2023
CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosisAndrew J Dunbar, Dongjoo Kim, Min Lu, et al.
Cancer Cell|July 16, 2015
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative NeoplasmsSara C Meyer, Matthew D Keller, Sophia Chiu, et al.
Blood|January 10, 2022
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemiaJohn Mascarenhas, Heidi E Kosiorek, Josef T Prchal, et al.
Blood|June 29, 2022
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic dataDaniel A Arber, Attilio Orazi, Robert P Hasserjian, et al.
Pageof 21

Showing results (201-210 of 204) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 204 results.
Blood|February 17, 2023
CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosisAndrew J Dunbar, Dongjoo Kim, Min Lu, et al.
Cancer Cell|July 16, 2015
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative NeoplasmsSara C Meyer, Matthew D Keller, Sophia Chiu, et al.
Blood|January 10, 2022
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemiaJohn Mascarenhas, Heidi E Kosiorek, Josef T Prchal, et al.
Blood|June 29, 2022
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic dataDaniel A Arber, Attilio Orazi, Robert P Hasserjian, et al.
Pageof 21